Indivior PLC’s (INDV) Buy Rating Reiterated at Stifel Nicolaus
Indivior PLC (LON:INDV)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a report released on Friday. They presently have a GBX 400 ($5.17) target price on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 35.36% from the stock’s previous close.
INDV has been the topic of a number of other research reports. Jefferies Group LLC dropped their target price on shares of Indivior PLC from GBX 540 ($6.97) to GBX 358 ($4.62) and set a “buy” rating on the stock in a research report on Friday, September 8th. Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 280 ($3.62) target price on shares of Indivior PLC in a research report on Tuesday, September 5th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 470 ($6.07) target price on shares of Indivior PLC in a research report on Friday, September 1st. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 470 ($6.07) target price on shares of Indivior PLC in a research report on Thursday, August 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of GBX 395.50 ($5.11).
Indivior PLC (INDV) traded up 1.56% during mid-day trading on Friday, reaching GBX 300.10. 1,716,388 shares of the company traded hands. The stock has a 50-day moving average of GBX 371.14 and a 200 day moving average of GBX 336.83. The stock’s market capitalization is GBX 2.16 billion. Indivior PLC has a 52-week low of GBX 246.50 and a 52-week high of GBX 421.50.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.